EP0784437A1 - Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine - Google Patents

Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine

Info

Publication number
EP0784437A1
EP0784437A1 EP95934657A EP95934657A EP0784437A1 EP 0784437 A1 EP0784437 A1 EP 0784437A1 EP 95934657 A EP95934657 A EP 95934657A EP 95934657 A EP95934657 A EP 95934657A EP 0784437 A1 EP0784437 A1 EP 0784437A1
Authority
EP
European Patent Office
Prior art keywords
fatty acids
phospholipids
fat
arachidonic acid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP95934657A
Other languages
German (de)
English (en)
Other versions
EP0784437B1 (fr
Inventor
Gerhard Kohn
Günther Sawatzki
Friedrich Schweikhardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milupa AG
Original Assignee
Milupa AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milupa AG filed Critical Milupa AG
Publication of EP0784437A1 publication Critical patent/EP0784437A1/fr
Application granted granted Critical
Publication of EP0784437B1 publication Critical patent/EP0784437B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C11/00Milk substitutes, e.g. coffee whitener compositions
    • A23C11/02Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
    • A23C11/04Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013Other fatty acid esters, e.g. phosphatides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof

Definitions

  • the invention relates to a formula food containing a fat mixture based on animal and vegetable including microbial oils and / or fats and lecithins containing long-chain, highly unsaturated fatty acids as well as a fat mixture of this type for producing a formula food.
  • LCP fatty acids Long-chain, highly unsaturated fatty acids with in particular 20 to 22 carbon atoms, so-called LCP fatty acids, are synthesized in the human organism by chain extension and desaturation from the essential fatty acids linoleic and linolenic acid. Accordingly, the linoleic acid (18-2w6) and the ⁇ -linolenic acid (18-3w3), which are a w6- and w3-desaturated fatty acid, have to be ingested with the diet.
  • the linoleic acid is the starting compound for the group of w6-LCP-, while the ⁇ -lin ⁇ lenic acid is the starting compound for the group of w3-LCP-fatty acids.
  • LCP fatty acids of which arachidonic acid (AA; 20-4w6) and docosahexaenoic acid (DHA; 22-6w3) are of the greatest importance, are found in the brain to a considerable extent, especially in the last third of pregnancy and in the first months after birth accumulated.
  • Prenatal LCP fatty acids are made available to the fetus through the placenta. After birth, the infant receives these fatty acids with the mother's milk, because human milk contains both w6- and w3-LCP, with arachidonic and docosahexaenoic acids being the most important quantitative components.
  • Formula foods or baby foods containing such LCP fatty acids are already known; in this regard, reference is made to EP-A 0 404 058, EP-A 0 231 904 and US-A 4 670 285.
  • the contents of the LCP fatty acids are more or less close to the values of the total lipids approximated by breast milk.
  • the amount of the supplemented LCP fatty acids is used, but not the form in which these fatty acids are bound.
  • the total lipids in breast milk are composed of approximately 97 to 99% triacylglycerides and approximately 0.5 to 2% phospholipids.
  • free fatty acids, mono- and diacylglycerides, glycolipids and cholesterol and phytosterols also occur in breast milk.
  • the LCP fatty acids in breast milk are approximately 90 to 95% in the form of triglycerides and approximately 5 to 10% in the form of phospholipids.
  • EP-A-0 484 266 takes the incorrect view that the majority of the long-chain, highly unsaturated fatty acids (LCP fatty acids) are present in human milk in the form of phospholipids.
  • LCP fatty acids in the form of phospholipids from the brain fat of mammals to dietary foods is therefore recommended there.
  • the LCP contents of fish oil are also adapted to the ratios of the total lipids in breast milk.
  • the object of the present invention is to provide an improved formula food and an improved fat mixture for the production of this formula food which comes as close as possible to the nutritional quality of breast milk.
  • the formulas or fat blends representing the state of the art are adjusted (in absolute terms) to the ratios of the total lipids from breast milk in terms of the LCP fatty acids of interest here. It has now surprisingly been found that the total amount of LCP fatty acids in the formula can be reduced if the arachidonic acid and docosahexaenoic acid are partly available in the form of phospholipids in the amount according to the invention.
  • the addition of LCP fatty acids in the form of tri-glycerides as is the case with the known formula foods, can thus be considerably reduced and the costs for supplementation with LCP fatty acids can thereby be reduced.
  • Arachidonic acid both in triglyceride form and in phospholipid form, is added to a formula in the amounts claimed according to the invention.
  • the weight ratio of the arachidonic acid present in the form of triglycerides to the docosahexaenoic acid present in the form of triglycerides is 0.5: 1 to 20: 1.
  • the weight ratio of arachidonic acid present in the form of phospholipids to docosahexaenoic acid present in the form of phospholipids is preferably 0.5: 1 to 1: 5.
  • the arachidonic acid and the docosahexaenoic acid are preferably in the form of phosphoglycerolipids, more preferably in the form of phosphatidylcholine and phosphatidylethanolamine.
  • the invention further relates to a fat mixture which contains the LCP fatty acids in the stated form and in the stated amounts.
  • This fat mixture is suitable for the production of baby and premature baby food, in particular baby milk food.
  • formula food is understood to mean any "artificial" formula food that is produced without the use of human milk or without the use of the components of human milk.
  • the formula food according to the invention and of course also the fat mixture according to the invention can be produced by:
  • Animal and vegetable oils and fats containing triacylglycerides are mixed with animal, vegetable and / or microbial phospholipids (lecithins) which contain LCP fatty acids.
  • Animal fats can be, for example, butterfat, organ fats such as kidney, liver and brain fat, and
  • Oils from mono- and dicotyledonous plants can be used as vegetable oils.
  • oils from microbial origin (SCO) or algae and mushroom oils can be used.
  • the LCP fatty acids arachidonic and docosahexaenoic acid used in the form of phospholipids are introduced into the fat mixture or formula food according to the invention in the form of phospholipids of animal, vegetable and microbial origin.
  • These phospholipids include lecithins from fish, from other marine organisms, such as mammals, krill, cephalopods, etc., from egg lipids, from animal brain and other organ lipids and from macro and microalgae and / or from microorganisms .
  • a finished formula eg infant milk
  • a fat content 4% or 4 g / 100 ml
  • the arachidonic acid present in the form of phospholipids makes 0.6 to 15 mg and the Docosahexaenoic acid present in the form of phospholipids from 0.3 to 10 mg per 100 ml of formula food.
  • the invention also relates to a method for producing a fat mixture according to the invention.
  • animal, vegetable and / or microbial oils and / or fats which contain no LCP fatty acids or only low LCP fatty acid fractions (in particular, these are fats and oils which have been used previously for the production of non-LCP) - Fatty acids supplemented formula foods were used), with a source of arachidonic acid and docosahexaenic acid, which are in the form of phospholipids, or with animal, vegetable, including microbial oils, fats and / or lecithins, the arachidonic acid and docosahexaenoic acid in Contain form of phospholipids, mixed in a known manner such that these arachidonic acid and docosahexaenoic acid meet the values specified in claims 1 to 4.
  • oils, fats and / or lecithins can be mixed according to the prior art; in this regard, reference is made, for example, to EP-A 0 231 904 and EP-A 0 404 058.
  • a formula food can also be produced from this fat mixture according to the prior art.
  • Table 1 below shows the composition of five fat mixtures according to the invention and the resulting fatty acid pattern. These fat mixtures are produced by mixing the fat raw materials listed in Table 1.
  • Table 2 shows the composition of various formula foods according to the invention, which were produced using the fat mixtures explained in Table 1. To produce the formula foods listed in Table 2, the constituents shown there are mixed with one another. Ready-to-drink formula foods can be made from it by adding drinking water. 13 g of the composition or formula described in Table 2 are added to 90 ml of drinking water and mixed. 100 ml of the ready-to-drink formula foods obtained in this way have the absolute contents of the fatty acids mentioned there in Table 3 which follows. The short designation or nomenclature for the fatty acids used in the present documents is explained in more detail, inter alia, in "Lipid Analysis” by William W. Christie, Pergamon Press, 1973.
  • composition of several fat mixtures according to the invention and the resulting fatty acid pattern (data in% by weight)
  • Example 1 Example 2 Example 3 Example 4 Example 5
  • Sunflower oil (hyp.) 10 10 10 10 10 10 palm oil 25 24 21.5 21.5 21.5 coconut / palm kernel fat 14 13 12 10 7 canola oil 5 5 5 5 5 soy oil 14 13.5 13.5 11.5 9.5 Lecithin 1 2 4 8 12 17
  • composition of various formula foods according to the invention (details in g)
  • Example 1 Example 2 Example 3 Example 4 Example 5
  • DHA Docosahexaenic acid
  • Example 1 Example 2 Example 3 Example 4 Example 5
  • DHA Docosahexaenoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Health & Medical Sciences (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Edible Oils And Fats (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP95934657A 1994-10-05 1995-10-02 Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine Expired - Lifetime EP0784437B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4435535 1994-10-05
DE4435535 1994-10-05
PCT/EP1995/003899 WO1996010922A1 (fr) 1994-10-05 1995-10-02 Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine

Publications (2)

Publication Number Publication Date
EP0784437A1 true EP0784437A1 (fr) 1997-07-23
EP0784437B1 EP0784437B1 (fr) 1998-07-08

Family

ID=6529982

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95934657A Expired - Lifetime EP0784437B1 (fr) 1994-10-05 1995-10-02 Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine

Country Status (8)

Country Link
EP (1) EP0784437B1 (fr)
JP (1) JPH10508193A (fr)
AT (1) ATE167983T1 (fr)
CA (1) CA2201931C (fr)
DE (1) DE59502779D1 (fr)
DK (1) DK0784437T3 (fr)
ES (1) ES2118629T3 (fr)
WO (1) WO1996010922A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080787A (en) * 1997-02-21 2000-06-27 Abbott Laboratories Methods for reducing the incidence of necrotizing enterocolitis
CN1200701C (zh) 1997-02-21 2005-05-11 艾博特公司 降低坏死性小肠结肠炎发生率的组合物
SE9702630D0 (sv) * 1997-07-07 1997-07-07 Scotia Lipidteknik Ab Satiety product
US6294206B1 (en) * 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6495599B2 (en) 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
EP1181870A1 (fr) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Emulsion de lipides constituant une source alimentaire de vitamine F plus equilibrée
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
EP1643862A1 (fr) * 2003-06-24 2006-04-12 University of Kansas Medical Center Formule pour bebes
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
CA2662260C (fr) * 2006-08-29 2015-10-27 Martek Biosciences Corporation Utilisation d'huiles dpa(n-6) dans une formule pour enfant en bas age
EP3593797A1 (fr) 2006-12-28 2020-01-15 Suntory Holdings Limited Agent de régénération des nerfs
CN101909467B (zh) 2007-11-01 2013-04-24 恩兹默泰克有限公司 用于婴儿营养的脂质混合物
EP2100897A1 (fr) * 2008-01-30 2009-09-16 BNLfood Investments SARL Composition à base de lécithine et son utilisation dans les aliments
EP2258216A1 (fr) * 2009-06-02 2010-12-08 Nestec S.A. Composition nutritionnelle pour supporter le développement cérébral et fonction des tout-petits
EP2554058A4 (fr) 2010-03-31 2013-12-25 Vegenat S A Complément alimentaire fonctionnel spécialement destiné à la nutrition, à la prévention et à l'atténuation d'altérations neurologiques ou neurodégénératives ou de troubles cognitifs
WO2011121150A1 (fr) 2010-03-31 2011-10-06 Vegenat, S.A. Produit alimentaire entéral ou oral spécialement destiné à la nutrition, à la prévention et à l'atténuation d'altérations neurologiques ou neurodégénératives ou de troubles cognitifs
WO2015069097A1 (fr) 2013-11-08 2015-05-14 N.V. Nutricia Efficacité du dha alimentaire-phospholipide pour l'accrétion de dha et dpa dans le cerveau du nouveau-né
WO2021058632A1 (fr) 2019-09-24 2021-04-01 Société des Produits Nestlé SA Glycyrrhiza et prévention de l'oxydation des lc-pufa
JP2023530076A (ja) 2020-06-17 2023-07-13 ソシエテ・デ・プロデュイ・ネスレ・エス・アー コーヒー生豆の脱カフェイン処理に由来するサイドストリーム生成物によるlc-pufaの安定化

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
SE9101642D0 (sv) * 1991-05-30 1991-05-30 Kabi Pharmacia Ab Phospholipids
DE4219360C2 (de) * 1992-06-12 1994-07-28 Milupa Ag Verfahren zur Gewinnung von Lipiden mit einem hohen Anteil von langkettig-hochungesättigten Fettsäuren
DE4407917C2 (de) * 1993-03-15 2002-12-12 Sueddeutsche Kalkstickstoff Verfahren zur Gewinnung von Lipidfraktionen aus pulverförmigen Eiprodukten
DE19505305A1 (de) * 1994-02-24 1995-08-31 Milupa Ag Stabilisierte Lipidzusammensetzung mit langkettig-hochungesättigten Fettsäuren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9610922A1 *

Also Published As

Publication number Publication date
ATE167983T1 (de) 1998-07-15
ES2118629T3 (es) 1998-09-16
EP0784437B1 (fr) 1998-07-08
DK0784437T3 (da) 1999-04-19
DE59502779D1 (de) 1998-08-13
CA2201931A1 (fr) 1996-04-18
CA2201931C (fr) 2004-08-10
WO1996010922A1 (fr) 1996-04-18
JPH10508193A (ja) 1998-08-18

Similar Documents

Publication Publication Date Title
EP0784437B1 (fr) Melange de graisses contenant des phospholipides avec des acides gras polyinsatures a longue chaine
EP0231904B1 (fr) Mélange gras riche en acides polyéniques et son utilisation dans la préparation d'aliments pour nourrissons
EP0404058B1 (fr) Mélange gras, procédé pour sa préparation et son application
DE60125176T2 (de) Verbesserte verfahren zum hinzufuegen mehrfach gesaettigter fettsaeuren in milch
DE69727138T2 (de) Dietetische baby nahrungsmittel mit konjugierten linoleinsäuren
DE3787503T2 (de) Fette und Öle mit einer verbesserten Verdaulichkeit und Absorptionsfähigkeit.
DE69636307T2 (de) Erhöhung des hdl-spiegels und des hdl/ldl verhältnisses im menschlichen serum durch eine ausbalancierte mischung gesättigter und mehrfach ungesättigter diätfettsäuren
DE69823548T2 (de) Verwendung von mehrfach ungesättigten fettsäuren zur vorbeugung von nekrotizierender enterokolitis
DE68907477T2 (de) Essbare Öl-/Fett-Zusammensetzungen.
EP1041896B1 (fr) Melange de corps gras
DE69735278T3 (de) Verfahren zur Herstellung von ungesättigte Fettsäuren enthaltendem Öl
DE2127134A1 (de) Fettpraparate fur Nahrungsmittel, Verfahren zu ihrer Herstellung und ihrer Verwendung
DE3877792T2 (de) Verfahren zur zubereitung einer emulgierten fett-zusammensetzung.
DE2650980C2 (de) Verfahren zur Herstellung eines Aufstrichmittels mit niedrigem Kaloriengehalt
DE68919712T2 (de) Strukturiertes Lipid enthaltend Milchfett.
DE60132523T2 (de) Pharmazeutische- und Nahrungsmittelzusammensetzungen mit "Holzalkohol" und "Holzsterol" zur Senkung des Serumcholesterins
DE60005911T2 (de) Kuhmilch und Kuhfutter um eine solche Milch zu erhalten
EP0148303A1 (fr) Composition diététique
WO1992020241A1 (fr) Preparation de substances nutritives
DE3230103C2 (fr)
DE19956400B4 (de) Therapeutisch wirksame Zusammensetzung, ein Verfahren zu ihrer Herstellung und ihre Verwendung
DE19516982C2 (de) Verwendung einer Milchkuh-Futterzusammensetzung
DE69103554T2 (de) Essbare Emulsionen.
DE19505305A1 (de) Stabilisierte Lipidzusammensetzung mit langkettig-hochungesättigten Fettsäuren
DE1792636A1 (de) Verfahren zur Herstellung von Nahrungsmitteln

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19971008

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

ITF It: translation for a ep patent filed

Owner name: BARZANO' E ZANARDO MILANO S.P.A.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT

REF Corresponds to:

Ref document number: 167983

Country of ref document: AT

Date of ref document: 19980715

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TROESCH SCHEIDEGGER WERNER AG

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 19980710

REF Corresponds to:

Ref document number: 59502779

Country of ref document: DE

Date of ref document: 19980813

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2118629

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19981002

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19980709

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20141027

Year of fee payment: 20

Ref country code: PT

Payment date: 20140403

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20141024

Year of fee payment: 20

Ref country code: ES

Payment date: 20141024

Year of fee payment: 20

Ref country code: DE

Payment date: 20141124

Year of fee payment: 20

Ref country code: IE

Payment date: 20141021

Year of fee payment: 20

Ref country code: FR

Payment date: 20141021

Year of fee payment: 20

Ref country code: GR

Payment date: 20141024

Year of fee payment: 20

Ref country code: GB

Payment date: 20141024

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20141022

Year of fee payment: 20

Ref country code: NL

Payment date: 20141023

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20141023

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20141020

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 59502779

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20151002

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20151001

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20151002

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20151001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151001

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 167983

Country of ref document: AT

Kind code of ref document: T

Effective date: 20151002

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151002

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 980402055

Country of ref document: GR

Effective date: 20151003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20151003